ClinicalTrials.gg
CompletedNCT03110562BOSTONUpdated Aug 21, 2024Results posted

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

A Phase 3 interventional study of Selinexor and Bortezomib in Multiple Myeloma, sponsored by Karyopharm Therapeutics Inc. Completed at 157 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Karyopharm Therapeutics Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing selinexor in Multiple Myeloma — 12 open to participants now, 21 under way, 3 of them phase 3. selinexor · Multiple Myeloma.

Enrollment
2nd of 38
402 · median 45
Started
2017
with 1 other
Phase 3
4 of 38
1 open now
Registered
9th of 38
by date
Lead sponsor
6 of 38
Karyopharm Therapeutics Inc

Among the 38 studies testing selinexor in Multiple Myeloma, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 3, and was the 9th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 38 studies testing selinexor in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About selinexor

selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing selinexor in Multiple Myeloma, or all of them as a file.
02

Study summary

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes selinexor (i.e., SVdX or SdX) will be allowed at the point of IRC-confirmed objective disease progression per the IMWG criteria for patients in the Vd Arm.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Relapsed or Refractory Multiple Myeloma
  • RRMM
  • Bortezomib
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed MM with per IMWG guidelines as defined by at least 1 of the following:

    1. Serum M-protein ≥ 0.5 g/dL (> 5 g/L) by serum protein electrophoresis (SPEP) or for immunoglobulin (Ig) A myeloma, by quantitative serum IgA levels; or
    2. Urinary M-protein excretion at least 200 mg/24 hours; or
    3. Serum free light chain (FLC) ≥ 100 mg/L, provided that the serum FLC ratio is abnormal (normal FLC ratio: 0.26 to 1.65).
  2. Had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens. Induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 anti-MM regimen.
  3. Documented evidence of progressive MM (based on the Investigator's determination according to the modified IMWG response criteria) on or after their most recent regimen.
  4. Prior treatment with bortezomib or other Proteasome Inhibitor (PI) is allowed, provided all of the following criteria are met:

    1. Best response achieved with prior bortezomib at any time was ≥ PR and with the last PI (PI therapy (alone or in combination) was ≥ PR, AND
    2. Participant did not discontinue bortezomib due to ≥ Grade 3 related toxicity, AND
    3. Must have had at least a 6-month PI-treatment-free interval prior to Cycle 1 Day 1 (C1D1) of study treatment.
  5. Must have an Status score of 0, 1, or 2.
  6. Written in accordance with federal, local, and institutional guidelines.
  7. Age ≥18 years.
  8. Resolution of any non-hematological toxicities (if any) from previous treatments to ≤ Grade 1 by C1D1. Patients with chronic, stable Grade 2 non-hematological toxicities may be included following approval from the Medical Monitor.
  9. Adequate hepatic function within 28 days prior to C1D1.

    1. Total \<1.5 × (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \<3 × ULN), and
    2. (AST) and alanine aminotransferase (ALT) normal to \<2 × ULN.
  10. Adequate renal function within 28 days prior to C1D1 (estimated [CrCl] of ≥20 mL/min, calculated using the formula of Cockroft and Gault):

(140-Age) × Mass (kg)/(72 × creatinine mg/dL) Multiply by 0.85 if the patient is female, or if CrCl is ≥20 mL/min as measured by 24-hour urine collection.

  1. Adequate hematopoietic function within 7 days prior to C1D1: total white blood cell (WBC) count ≥1500/mm3, ≥1000/mm3, ≥8.5 g/dL and count ≥75,000/mm3 (patients for whom \< 50% of bone marrow nucleated cells are plasma cells) or ≥50,000/mm3 (patients for whom ≥50% of bone marrow nucleated cells are plasma cells).
  1. Patients receiving hematopoietic growth factor support, including erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (eg, eltrombopag, romiplostim, or interleukin-11) must have a 2-week interval between growth factor support and the Screening assessments, but they may receive growth factor support during the study.
  2. Patients must have:

    • At least a 2-week interval from the last red blood cell (RBC) transfusion prior to the Screening hemoglobin assessment, and
    • At least a 1-week interval from the last platelet transfusion prior to the Screening platelet assessment.

However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study.

  1. Female patients of must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of throughout the study and for 3 months following the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Prior exposure to a SINE compound (i.e. an XPO-1 inhibitor), including selinexor.
  2. Prior that required treatment or has shown evidence of recurrence (except for non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the 5 years prior to randomization. Cancer treated with curative intent for >5 years previously and without evidence of recurrence will be allowed.
  3. Has any concurrent medical condition or disease (e.g., uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures.
  4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to C1D1. Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.
  5. Active plasma cell leukemia.
  6. Documented systemic light chain amyloidosis.
  7. MM involving the central nervous system.
  8. Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.
  9. Spinal cord compression.
  10. Greater than Grade 2 neuropathy or ≥ Grade 2 neuropathy with pain at baseline, regardless of whether or not the patient is currently receiving medication
  11. Known intolerance, , or to .
  12. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy (including therapies) ≤ 2 weeks prior to C1D1. Localized radiation to a single site at least 1 week before C1D1 is permitted. Glucocorticoids within 2 weeks of C1D1 are permitted. Patients on long-term glucocorticoids during Screening do not require a but must be able to tolerate the specified dexamethasone dose in this study.
  13. Prior stem cell transplantation \< 1 month or allogeneic stem cell transplantation \< 4 months prior to C1D1.
  14. Active (after allogeneic stem cell transplantation) at C1D1.
  15. Pregnant or breastfeeding females.
  16. Body Surface Area \< 1.4 m² at baseline, calculated by the Dubois or Mosteller method.
  17. of \< 4 months.
  18. Major surgery within 4 weeks prior to C1D1.
  19. Active, unstable cardiovascular function:

    1. Symptomatic ischemia, or
    2. Uncontrolled conduction abnormalities (e.g., patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first-degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or
    3. Congestive heart failure of Class ≥ 3 or known \< 40%, or
    4. Myocardial infarction within 3 months prior to C1D1.
  20. Known active (HIV) infection or HIV seropositivity
  21. Known active hepatitis A, B, or C infection; or known to be positive for virus ribonucleic acid (RNA) or virus surface antigen.
  22. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.
  23. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give .
  24. Contraindication to any of the required concomitant drugs or supportive treatments.
  25. Patients unwilling or unable to comply with the protocol, including providing 24-hour urine samples for urine protein electrophoresis at the required time points.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
402 participants (actual)

Study arms

  • Experimental
    SVd Arm: Selinexor + Bortezomib + Dexamethasone

    Participants received a fixed oral dose of 100 milligrams (mg) selinexor tablets (5 tablets of 20 mg each) once weekly (QW) on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with subcutaneous (SC) injection of 1.3 milligrams per square meter (mg/m\^2) bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone twice weekly (BIW) on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.

    Drug: Selinexor · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Vd Arm: Bortezomib + Dexamethasone

    Participants received SC injection of 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by greater than or equal to (\>=) 9 cycles on Days 1, 8, 15, and 22 of each 35-day cycle, and received oral dose of 20 mg dexamethasone BIW on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles and for cycles \>= 9 on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.

    Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    SVdX Arm: Selinexor + Bortezomib + Dexamethasone

    Participants in the VD arm who had IRC-confirmed PD and were able to tolerate continued bortezomib treatment had crossed over to receive fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with SC injection of 1.3 mg/m\^2 bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.

    Drug: Selinexor · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    SdX Arm: Selinexor + Dexamethasone

    Participants in the VD arm who had IRC-confirmed PD and were unable to tolerate continued bortezomib treatment had crossed over to receive fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.

    Drug: Selinexor · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)

    PFS was defined as time from date of randomization until the first date of IRC-confirmed PD, per International Myeloma Working Group (IMWG) response criteria, or death due to any cause, whichever occurs first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; c) urine M-protein (absolute increase must be \>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \>=10%).

    Time frame: From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)

Secondary outcomes

  1. SVd/Vd Arm: Overall Response Rate (ORR) as Assessed by IRC

    ORR was defined as the percentage of the participants who achieved any confirmed partial response (PR) or better PR, complete response (CR), very good partial response (VGPR) or stringent complete response (sCR) based on the IRC's response outcome assessments, according to the International Myeloma Working Group (IMWG) response criteria, before IRC-confirmed PD or initiating a new MM treatment. PR: \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined as Normal free light chain (FLC) ratio + Absence of clonal cells by immunohistochemistry.

    Time frame: From date of randomization until disease progression or initiating a new MM treatment (up to 33 months)

  2. SVd/Vd Arm: Percentage of Participants With Response Rate of Very Good Partial Response (VGPR) or Better Based on IRC Assessment

    Response rate was defined as percentage of participants with responses of VGPR, at any time prior to IRC-confirmed PD or initiating a new MM treatment. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours.

    Time frame: From date of randomization until confirmed PD or initiating a new MM treatment (up to 33 months)

  3. SVd/Vd Arm: Number of Participants With at Least One Grade Greater Than or Equal to [>=] 2 Peripheral Neuropathy Events

    Peripheral neuropathy events was assessed using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The grade ranges from Grade 1 (mild, asymptomatic, or mild symptoms) to Grade 5 (death related to an adverse event). Grade 2 indicates a moderate condition that may require minimal intervention and can limit certain daily activities. Grade 3 represents severe symptoms that are not immediately life-threatening but may lead to hospitalization and restrict self-care activities. Grade 4 denotes life-threatening consequences requiring urgent intervention. Number of participants experiencing at least one Grade \>= 2 peripheral neuropathy event have been reported.

    Time frame: From first dose of study treatment to 30 days after the last dose of study treatment inclusive, or the day before the start of new anti-MM treatment, whichever occurs first (up to 33 months)

  4. SVd/Vd Arm: Overall Survival (OS)

    OS was defined as the time from the date of randomization until either the date of death due to any cause or until the participant is lost to follow-up, for all participants.

    Time frame: From date of randomization to the date of death or censored date, whichever occurred first (up to 45 months)

  5. SVd/Vd Arm: Duration of Response (DOR) as Assessed by IRC

    DOR was defined as the duration of time from the first occurrence of an IRC confirmed response of at least (\>=) PR until the first date of IRC-confirmed PD or death due to any cause, whichever occurred first. PR: \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; PD: Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>= 5 g/dL; Urine M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

    Time frame: From the first documentation of response to the first documentation of PD or death, whichever occurred first (up to 45 months)

  6. SVdX Arm: Overall Response Rate (ORR1) as Assessed by IRC During SVdX Treatment

    ORR was defined as the percentage of the participants who achieved a confirmed partial response or better (i.e., PR, VGPR, CR, or sCR) based on the IRC's response outcome assessments, according to the IMWG response criteria. PR: \>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>=90% or \<200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; or sCR: CR as defined as Normal FLC ratio+ Absence of clonal cells in bone marrow biopsy by immunohistochemistry.

    Time frame: From date of first SVdX treatment until disease progression or initiating a new MM treatment (up to 33 months)

  7. SVdX Arm: Progression Free Survival1 (PFS1) as Assessed by IRC During SVdX Treatment

    PFS1 is defined as the duration of time from the date of the first dose of the SVd treatment after crossover from the Vd arm until the first date of PD or death due to any cause, whichever occurred first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; c) urine M-protein (absolute increase must be \>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \>=10%).

    Time frame: From date of first SVdX treatment until IRC-confirmed documented PD or death or censored date, whichever occurred first (up to 33 months)

  8. SVd/Vd Arm: Time-to-next-treatment (TTNT) in Participants Randomized to the SVd and Vd Arm Who Received Treatment After SVd/Vd

    TTNT is defined as the duration from date of randomization to start of next anti-MM treatment or death, whichever occurs first. For patients without an event, their follow-up time will be censored at the date of discontinuation from study, or last participating visit on or before database cutoff date, whichever occurs first.

    Time frame: From date of randomization to start of next anti-MM treatment or death, whichever occurred first (up to 33 months)

  9. SVd/Vd Arm: Time To Response (TTR) in Participants Randomized to the SVd and Vd Arm

    TTR was defined as duration from randomization to the date of first IRC-confirmed PR or better (i.e., PR, VGPR, CR, or sCR) before IRC-confirmed PD or initiating a new MM treatment per IMWG response criteria. The participants who do not achieve IRC-confirmed PR or better response will be censored at the date of last disease assessment on or before database cutoff date. PR: \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or sCR: Normal free light chain (FLC) ratio + Absence of clonal cells by immunohistochemistry.

    Time frame: From randomization to the date of first IRC-confirmed PR or better (i.e., PR, VGPR, CR, or sCR), whichever occurred first (up to 33 months)

  10. SVd/Vd/SVdx Arm: Progression Free Survival 2 (PFS 2) in Participants Randomized to the SVd and Vd Arm Who Received Post-SVd/Vd/SVdX Treatment

    PFS 2 was defined as the duration of time from the date of the first dose of the treatment after SVd/Vd/SVdX until the first date of PD on treatment after SVd/Vd/SVdX or death due to any cause, whichever occurred first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; c) urine M-protein (absolute increase must be \>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \>=10%).

    Time frame: From date of first dose of post-SVd/Vd/SVdX treatment to the date of first PD on post-SVd/Vd/SVdX treatment, or death due to any cause (up to 33 months)

  11. SVd/Vd Arm: Change From Baseline in Participant-Reported Peripheral Neuropathy (PN) Assessed by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire- Chemotherapy-Induced PN 20 (EORTC- QLQ-CIPN20) Total Scores

    The EORTC QLQ-CIPN20 instrument is a 20-item QoL instrument, which has been developed to elicit patients' experience of symptoms and functional limitations related to CIPN. The QLQ-CIPN20 contains 20 items assessing sensory (9 items), motor (8 items), and autonomic symptoms (3 items) containing a 4-point Likert scale (1= not at all, 2= a little, 3= quite a bit, and 4= very much), participants indicate the degree to which they have experienced sensory, motor, and autonomic symptoms during the past week. Sensory raw scale scores range from 1 to 36, motor raw scale scores range from 1 to 32, and autonomic raw scale scores range from 1 to 12 for men and 1-8 for women (erectile function item is excluded). All scale scores are linearly converted to a total score with range of 0-100 scale, with higher scores indicating more symptom burden.

    Time frame: Svd Arm: Baseline up to End of treatment (EOT) (at Day 820); Vd Arm: Baseline up to EOT (at Day 848)

07

Results

Posted Jul 8, 2021

Participant flow

The study was conducted at 165 investigative sites in 21 countries. A total of 402 participants were enrolled and randomized, of which 399 participants received SVd treatment (195 participants) or Vd treatment (204 participants).

Initial Treatment Period
Participant flow — Initial Treatment Period
MilestoneSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + DexamethasoneSVdX Arm: Selinexor + Bortezomib + DexamethasoneSdX Arm: Selinexor + Dexamethasone
Started19520700
Treated19520400
Intent-to-treat (itt) population19520700
Safety population19520400
Completed0000
Not completed19520700
Withdrew: Disease progression1100
Withdrew: Withdrawal by subject394100
Withdrew: Adverse event1000
Withdrew: Death748200
Withdrew: Lost to follow-up13800
Withdrew: Protocol deviation1000
Withdrew: Physician decision2100
Withdrew: Participants withdrawn due to company goals596700
Withdrew: Other5400
Withdrew: Randomized but never treated0300
Crossover Period
Participant flow — Crossover Period
MilestoneSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + DexamethasoneSVdX Arm: Selinexor + Bortezomib + DexamethasoneSdX Arm: Selinexor + Dexamethasone
Started006614
Completed0000
Not completed006614
Withdrew: Disease progression0010
Withdrew: Withdrawal by subject0086
Withdrew: Death00373
Withdrew: Lost to follow-up0001
Withdrew: Other0011
Withdrew: Participants withdrawn due to company goals00193

Outcome measures

PrimarySVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)

PFS was defined as time from date of randomization until the first date of IRC-confirmed PD, per International Myeloma Working Group (IMWG) response criteria, or death due to any cause, whichever occurs first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; c) urine M-protein (absolute increase must be \>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \>=10%).

Time frame:
From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)
Reported as:
Median · Months
SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)
MonthsSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + Dexamethasone
SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)13.93 (11.73 to NA)9.46 (8.11 to 10.78)
Statistical analysis
  • SVd Arm: Selinexor + Bortezomib + Dexamethasone vs Vd Arm: Bortezomib + Dexamethasone · Stratified Log-rank Test · p = 0.0075 (One Sided P-value) · Hazard ratio (hr): 0.7020 · 95% CI 0.5279 to 0.9335Based on stratified Cox Proportional Hazard model with Efron's Method of handling ties.
SecondarySVd/Vd Arm: Overall Response Rate (ORR) as Assessed by IRC

ORR was defined as the percentage of the participants who achieved any confirmed partial response (PR) or better PR, complete response (CR), very good partial response (VGPR) or stringent complete response (sCR) based on the IRC's response outcome assessments, according to the International Myeloma Working Group (IMWG) response criteria, before IRC-confirmed PD or initiating a new MM treatment. PR: \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined as Normal free light chain (FLC) ratio + Absence of clonal cells by immunohistochemistry.

Time frame:
From date of randomization until disease progression or initiating a new MM treatment (up to 33 months)
Reported as:
Number · Percentage of participants
SVd/Vd Arm: Overall Response Rate (ORR) as Assessed by IRC
Percentage of participantsSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + Dexamethasone
SVd/Vd Arm: Overall Response Rate (ORR) as Assessed by IRC76.4 (69.8 to 82.2)62.3 (55.3 to 68.9)
Statistical analysis
  • SVd Arm: Selinexor + Bortezomib + Dexamethasone vs Vd Arm: Bortezomib + Dexamethasone · Cochran-Mantel-Haenszel · p = 0.0012 (One Sided P-value) · Odds ratio (or): 1.9626 · 95% CI 1.2641 to 3.0471Analysis using Cochran-Mantel-Haenszel test stratified by region, prior PI therapies, number of prior anti-MM regimens, and R-ISS stage at screening.
SecondarySVd/Vd Arm: Percentage of Participants With Response Rate of Very Good Partial Response (VGPR) or Better Based on IRC Assessment

Response rate was defined as percentage of participants with responses of VGPR, at any time prior to IRC-confirmed PD or initiating a new MM treatment. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours.

Time frame:
From date of randomization until confirmed PD or initiating a new MM treatment (up to 33 months)
Reported as:
Number · Percentage of participants
SVd/Vd Arm: Percentage of Participants With Response Rate of Very Good Partial Response (VGPR) or Better Based on IRC Assessment
Percentage of participantsSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + Dexamethasone
SVd/Vd Arm: Percentage of Participants With Response Rate of Very Good Partial Response (VGPR) or Better Based on IRC Assessment44.6 (37.5 to 51.9)32.4 (26.0 to 39.2)
Statistical analysis
  • SVd Arm: Selinexor + Bortezomib + Dexamethasone vs Vd Arm: Bortezomib + Dexamethasone · Cochran-Mantel-Haenszel · p = 0.0082 (One Sided P-value) · Odds ratio (or): 1.6594 · 95% CI 1.0993 to 2.5049Analysis using Cochran-Mantel-Haenszel test stratified by region, prior PI therapies, number of prior anti-MM regimens, and R-ISS stage at screening.
SecondarySVd/Vd Arm: Number of Participants With at Least One Grade Greater Than or Equal to [>=] 2 Peripheral Neuropathy Events

Peripheral neuropathy events was assessed using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The grade ranges from Grade 1 (mild, asymptomatic, or mild symptoms) to Grade 5 (death related to an adverse event). Grade 2 indicates a moderate condition that may require minimal intervention and can limit certain daily activities. Grade 3 represents severe symptoms that are not immediately life-threatening but may lead to hospitalization and restrict self-care activities. Grade 4 denotes life-threatening consequences requiring urgent intervention. Number of participants experiencing at least one Grade \>= 2 peripheral neuropathy event have been reported.

Time frame:
From first dose of study treatment to 30 days after the last dose of study treatment inclusive, or the day before the start of new anti-MM treatment, whichever occurs first (up to 33 months)
Reported as:
Count of participants · Participants
SVd/Vd Arm: Number of Participants With at Least One Grade Greater Than or Equal to [>=] 2 Peripheral Neuropathy Events
ParticipantsSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + Dexamethasone
SVd/Vd Arm: Number of Participants With at Least One Grade Greater Than or Equal to [>=] 2 Peripheral Neuropathy Events4170
Statistical analysis
  • SVd Arm: Selinexor + Bortezomib + Dexamethasone vs Vd Arm: Bortezomib + Dexamethasone · Cochran-Mantel-Haenszel · p = 0.0013 (One Sided P-value) · Odds ratio (or): 0.5042 · 95% CI 0.3216 to 0.7906Stratified by Prior PI therapies (Yes or No), Number of prior anti-MM regimens (1 or \>1), and R-ISS stage at study entry (R-ISS Stage III versus R-ISS Stage I or II).
SecondarySVd/Vd Arm: Overall Survival (OS)

OS was defined as the time from the date of randomization until either the date of death due to any cause or until the participant is lost to follow-up, for all participants.

Time frame:
From date of randomization to the date of death or censored date, whichever occurred first (up to 45 months)
Reported as:
Median · Months
SVd/Vd Arm: Overall Survival (OS)
MonthsSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + Dexamethasone
SVd/Vd Arm: Overall Survival (OS)36.67 (30.19 to NA)32.76 (27.83 to NA)
Statistical analysis
  • SVd Arm: Selinexor + Bortezomib + Dexamethasone vs Vd Arm: Bortezomib + Dexamethasone · Stratified log-rank test · p = 0.2152 (One Sided P-value) · Hazard ratio (hr): 0.8764 · 95% CI 0.6313 to 1.2168Based on stratified Cox Proportional Hazard model with Efron's Method of handling ties.
SecondarySVd/Vd Arm: Duration of Response (DOR) as Assessed by IRC

DOR was defined as the duration of time from the first occurrence of an IRC confirmed response of at least (\>=) PR until the first date of IRC-confirmed PD or death due to any cause, whichever occurred first. PR: \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; PD: Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>= 5 g/dL; Urine M-protein (absolute increase must be \>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.

Time frame:
From the first documentation of response to the first documentation of PD or death, whichever occurred first (up to 45 months)
Reported as:
Median · Months
SVd/Vd Arm: Duration of Response (DOR) as Assessed by IRC
MonthsSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + Dexamethasone
SVd/Vd Arm: Duration of Response (DOR) as Assessed by IRC17.28 (12.55 to 26.25)12.88 (9.26 to 15.77)
SecondarySVdX Arm: Overall Response Rate (ORR1) as Assessed by IRC During SVdX Treatment

ORR was defined as the percentage of the participants who achieved a confirmed partial response or better (i.e., PR, VGPR, CR, or sCR) based on the IRC's response outcome assessments, according to the IMWG response criteria. PR: \>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>=90% or \<200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<=5% plasma cells in bone marrow; or sCR: CR as defined as Normal FLC ratio+ Absence of clonal cells in bone marrow biopsy by immunohistochemistry.

Time frame:
From date of first SVdX treatment until disease progression or initiating a new MM treatment (up to 33 months)
Reported as:
Number · Percentage of participants
SVdX Arm: Overall Response Rate (ORR1) as Assessed by IRC During SVdX Treatment
Percentage of participantsSVdX Arm: Selinexor + Bortezomib + Dexamethasone
SVdX Arm: Overall Response Rate (ORR1) as Assessed by IRC During SVdX Treatment19.0 (10.2 to 30.9)
SecondarySVdX Arm: Progression Free Survival1 (PFS1) as Assessed by IRC During SVdX Treatment

PFS1 is defined as the duration of time from the date of the first dose of the SVd treatment after crossover from the Vd arm until the first date of PD or death due to any cause, whichever occurred first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; c) urine M-protein (absolute increase must be \>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \>=10%).

Time frame:
From date of first SVdX treatment until IRC-confirmed documented PD or death or censored date, whichever occurred first (up to 33 months)
Reported as:
Median · Months
SVdX Arm: Progression Free Survival1 (PFS1) as Assessed by IRC During SVdX Treatment
MonthsSVdX Arm: Selinexor + Bortezomib + Dexamethasone
SVdX Arm: Progression Free Survival1 (PFS1) as Assessed by IRC During SVdX Treatment3.91 (3.48 to 6.93)
SecondarySVd/Vd Arm: Time-to-next-treatment (TTNT) in Participants Randomized to the SVd and Vd Arm Who Received Treatment After SVd/Vd

TTNT is defined as the duration from date of randomization to start of next anti-MM treatment or death, whichever occurs first. For patients without an event, their follow-up time will be censored at the date of discontinuation from study, or last participating visit on or before database cutoff date, whichever occurs first.

Time frame:
From date of randomization to start of next anti-MM treatment or death, whichever occurred first (up to 33 months)
Reported as:
Median · Months
SVd/Vd Arm: Time-to-next-treatment (TTNT) in Participants Randomized to the SVd and Vd Arm Who Received Treatment After SVd/Vd
MonthsSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + Dexamethasone
SVd/Vd Arm: Time-to-next-treatment (TTNT) in Participants Randomized to the SVd and Vd Arm Who Received Treatment After SVd/Vd16.13 (13.93 to NA)10.84 (9.82 to 13.40)
SecondarySVd/Vd Arm: Time To Response (TTR) in Participants Randomized to the SVd and Vd Arm

TTR was defined as duration from randomization to the date of first IRC-confirmed PR or better (i.e., PR, VGPR, CR, or sCR) before IRC-confirmed PD or initiating a new MM treatment per IMWG response criteria. The participants who do not achieve IRC-confirmed PR or better response will be censored at the date of last disease assessment on or before database cutoff date. PR: \>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>= 90% or to \< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or sCR: Normal free light chain (FLC) ratio + Absence of clonal cells by immunohistochemistry.

Time frame:
From randomization to the date of first IRC-confirmed PR or better (i.e., PR, VGPR, CR, or sCR), whichever occurred first (up to 33 months)
Reported as:
Median · Months
SVd/Vd Arm: Time To Response (TTR) in Participants Randomized to the SVd and Vd Arm
MonthsSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + Dexamethasone
SVd/Vd Arm: Time To Response (TTR) in Participants Randomized to the SVd and Vd Arm1.41 (1.35 to 1.51)1.61 (1.51 to 2.14)
SecondarySVd/Vd/SVdx Arm: Progression Free Survival 2 (PFS 2) in Participants Randomized to the SVd and Vd Arm Who Received Post-SVd/Vd/SVdX Treatment

PFS 2 was defined as the duration of time from the date of the first dose of the treatment after SVd/Vd/SVdX until the first date of PD on treatment after SVd/Vd/SVdX or death due to any cause, whichever occurred first. PD included increase of 25% from lowest confirmed response value in 1 or more of the following criteria: a) serum M-protein with absolute increase of \>= 0.5 gram per deciliter (g/dL); b) serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; c) urine M-protein (absolute increase must be \>= 200 mg per 24 hours); d) in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \[\>\] 10 mg/dL); e) in participants without measurable serum and urine M-protein levels and without measurable involved FLC levels: bone marrow plasma cell percentage irrespective of baseline status (absolute increase must be \>=10%).

Time frame:
From date of first dose of post-SVd/Vd/SVdX treatment to the date of first PD on post-SVd/Vd/SVdX treatment, or death due to any cause (up to 33 months)
Reported as:
Median · Months
SVd/Vd/SVdx Arm: Progression Free Survival 2 (PFS 2) in Participants Randomized to the SVd and Vd Arm Who Received Post-SVd/Vd/SVdX Treatment
MonthsSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm (Non-Crossover): Bortezomib + DexamethasoneSVdX Arm: Selinexor + Bortezomib + Dexamethasone
SVd/Vd/SVdx Arm: Progression Free Survival 2 (PFS 2) in Participants Randomized to the SVd and Vd Arm Who Received Post-SVd/Vd/SVdX Treatment6.60 (5.39 to 9.43)8.84 (5.78 to NA)3.88 (2.79 to NA)
SecondarySVd/Vd Arm: Change From Baseline in Participant-Reported Peripheral Neuropathy (PN) Assessed by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire- Chemotherapy-Induced PN 20 (EORTC- QLQ-CIPN20) Total Scores

The EORTC QLQ-CIPN20 instrument is a 20-item QoL instrument, which has been developed to elicit patients' experience of symptoms and functional limitations related to CIPN. The QLQ-CIPN20 contains 20 items assessing sensory (9 items), motor (8 items), and autonomic symptoms (3 items) containing a 4-point Likert scale (1= not at all, 2= a little, 3= quite a bit, and 4= very much), participants indicate the degree to which they have experienced sensory, motor, and autonomic symptoms during the past week. Sensory raw scale scores range from 1 to 36, motor raw scale scores range from 1 to 32, and autonomic raw scale scores range from 1 to 12 for men and 1-8 for women (erectile function item is excluded). All scale scores are linearly converted to a total score with range of 0-100 scale, with higher scores indicating more symptom burden.

Time frame:
Svd Arm: Baseline up to End of treatment (EOT) (at Day 820); Vd Arm: Baseline up to EOT (at Day 848)
Reported as:
Mean · Score on a Scale
SVd/Vd Arm: Change From Baseline in Participant-Reported Peripheral Neuropathy (PN) Assessed by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire- Chemotherapy-Induced PN 20 (EORTC- QLQ-CIPN20) Total Scores
Score on a ScaleSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + Dexamethasone
Total Sensory Score: Change at EOT3.38 ± 12.43611.17 ± 19.069
Total Motor Score: Change at EOT3.56 ± 14.5139.02 ± 18.662
Total Autonomic Score: Change at EOT10.41 ± 22.20110.92 ± 25.306

Adverse events

Collected over From date of randomization up to 45 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SVd Arm: Selinexor + Bortezomib + Dexamethasone74/195 (37.9%)109/195 (55.9%)193/195 (99%)
Vd Arm: Bortezomib + Dexamethasone82/204 (40.2%)79/204 (38.7%)197/204 (96.6%)
SVdX Arm: Selinexor + Bortezomib + Dexamethasone37/66 (56.1%)28/66 (42.4%)65/66 (98.5%)
SdX Arm: Selinexor + Dexamethasone3/14 (21.4%)7/14 (50%)14/14 (100%)
Most frequent serious events
Showing 10 of 170
Most frequent serious events
EventSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + DexamethasoneSVdX Arm: Selinexor + Bortezomib + DexamethasoneSdX Arm: Selinexor + Dexamethasone
PneumoniaInfections and infestations24/19525/2044/661/14
Lower respiratory tract infectionInfections and infestations4/1953/2040/661/14
Urinary tract infectionInfections and infestations4/1950/2042/661/14
Respiratory syncytial virus infectionInfections and infestations2/1951/2041/661/14
BronchiectasisRespiratory, thoracic and mediastinal disorders1/1950/2040/661/14
HyponatraemiaMetabolism and nutrition disorders0/1950/2040/661/14
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1950/2040/661/14
Haemorrhagic transformation strokeNervous system disorders0/1950/2040/661/14
CataractEye disorders9/1950/2041/660/14
AnaemiaBlood and lymphatic system disorders7/1953/2043/660/14
Most frequent other events
Showing 10 of 82
Most frequent other events
EventSVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + DexamethasoneSVdX Arm: Selinexor + Bortezomib + DexamethasoneSdX Arm: Selinexor + Dexamethasone
ThrombocytopeniaBlood and lymphatic system disorders120/19556/20433/664/14
NauseaGastrointestinal disorders98/19521/20426/664/14
Neuropathy peripheralNervous system disorders66/19599/20416/662/14
AnaemiaBlood and lymphatic system disorders72/19545/20430/663/14
Weight decreasedInvestigations51/19525/20418/666/14
FatigueGeneral disorders82/19537/20415/663/14
Decreased appetiteMetabolism and nutrition disorders70/19510/20419/664/14
DiarrhoeaGastrointestinal disorders63/19553/20419/663/14
CoughRespiratory, thoracic and mediastinal disorders36/19531/2044/664/14
AstheniaGeneral disorders48/19525/20410/660/14

Baseline characteristics

Intent-to-treat (ITT) population consisted of all participants who were randomized to the study treatment, regardless of whether or not they received the study treatment.

Age, Continuous
Age, Continuous(Years)SVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + DexamethasoneTotal
Mean65.3 ± 9.5666.7 ± 9.3566.0 ± 9.47
Sex: Female, Male
Sex: Female, Male(Participants)SVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + DexamethasoneTotal
Female8092172
Male115115230
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + DexamethasoneTotal
Race — Asian252550
Race — Black or African American4711
Race — White161165326
Race — Other011
Race — Missing5914
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SVd Arm: Selinexor + Bortezomib + DexamethasoneVd Arm: Bortezomib + DexamethasoneTotal
Ethnicity — Hispanic or Latino6511
Ethnicity — Not Hispanic or Latino171188359
Ethnicity — Not Reported141125
Ethnicity — Unknown426
Ethnicity — Missing011
08

Study locations

157 sites
  • Boca Raton Clinical Research (BRCR) Medical Center
    Plantation, Florida 33324, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Kaiser Permanente Hawaii
    Honolulu, Hawaii 96817, United States
  • McFarland Clinic
    Ames, Iowa 50010, United States
  • Stormont Vail Health Care (Cotton O'Neil Cancer Center )
    Topeka, Kansas 66606, United States
  • Commonwealth Hematology
    Danville, Kentucky 40422, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Central Care Cancer Center
    Bolivar, Missouri 65613, United States
  • The Valley Hospital Luckow Pavilion
    Paramus, New Jersey 07652, United States
  • Mount Sinai
    New York, New York 10029, United States
  • The Cancer Institute at St. Francis Hospital
    Roslyn, New York 11576, United States
  • Novant-Forsyth Memorial Hospital
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati Health
    Cincinnati, Ohio 45267, United States
  • Southwest Cancer Center of Oklahoma
    Lawton, Oklahoma 73505, United States
  • Kaiser Permanente Northwest OR
    Portland, Oregon 97210, United States
  • SCOR AnMed Health Cancer Center
    Anderson, South Carolina 29621, United States
  • Prairie Lakes Healthcare
    Watertown, South Dakota 57201, United States
  • Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Mater Misericordiae Limited and Mater Medical Research
    South Brisbane, Queensland 4101, Australia
  • Gold Coast University Hospital
    Southport, Queensland 4215, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • St. Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)
    Innsbruck, Austria
  • University Hospital Krems, Department of Internal Medicine II
    Krems, Austria
  • Medical University of Vienna
    Vienna, 1090, Austria
  • General Hospital Hietzing
    Vienna, 1130, Austria
  • Wilhelminen Hospital, Department of Internal Medicine I, Center for Oncology & Hematology
    Vienna, 1160, Austria
  • Jules Bordet Institute
    Brussels, 1000, Belgium
  • UCL Saint-Luc
    Brussels, Belgium
  • University Hospital Ghent
    Ghent, 9000, Belgium
  • General Hospital Delta
    Roeselare, 8800, Belgium
  • St. Augustinus Hospital
    Wilrijk, 2610, Belgium
  • University Multiprofile Hospital for Active Treatment, Sveti Georgi Clinic of Clinical Hematology
    Plovdiv, 4002, Bulgaria
  • University Multiprofile Hospital for Active Treatment, Sveti Ivan Rilski Clinic of Hematology
    Sofia, 1431, Bulgaria
  • Specialized Hospital for Active Treatment of Hematological Diseases, Clinic of Hematology, Dept. of Clinical Hematology
    Sofia, 1756, Bulgaria
  • Tom Baker Cancer Center/ Alberta Health Services
    Calgary, Alberta T2N 4Z6, Canada
  • Cross Cancer Institute / University of Alberta
    Edmonton, Alberta T6G 1Z2, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Queen Elizabeth II Health Sciences Center
    Halifax, Nova Scotia B3H 2Y9, Canada
  • North East Cancer Centre Sudbury
    Sudbury, Ontario P3E 5J1, Canada
  • Princess Margaret Cancer Research
    Toronto, Ontario M5G 1X5, Canada
  • Maisonneuve-Rosemont Hospital
    Montreal, Quebec H1T 2M4, Canada
  • Royal Victoria Hospital / McGill University
    Montreal, Quebec H3A 1A1, Canada
  • L'Hôtel-Dieu de Québec
    Quebec City, Quebec G1R 2J6, Canada
  • Saskatchewan Cancer Agency-Allan Blair Cancer Centre
    Regina, Saskatchewan S4T 7TI, Canada
  • Saskatoon Cancer Center
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • General University Hospital in Prague
    Praha 2, Prague 128 08, Czechia
  • University Hopsital Brno
    Brno, 625 00, Czechia
  • University Hospital Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • University Hospital Olomouc
    Olomouc, 775 20, Czechia
  • University Hospital Ostrava, Dept. of Hematooncology
    Ostrava, 708 52, Czechia
  • University Hospital Kralovske Vinohrady, Clinic of Internal Hematology
    Prague, 100 34, Czechia
  • Necker Children's Hospital, Department of Adult Hematology
    Paris, Ile De France 75015, France
  • Hospital Center Departmental La Roche-Sur-Yon
    La Roche-sur-Yon, 85925, France
  • Claude Huriez Hospital
    Lille, 59037, France
  • South Lyon Hospital Center
    Lyon, 69002, France
  • Brabois Adults Hospital, University Hospital Center of Nancy
    Nancy, 54511, France
  • Nantes University Hospital Center
    Nantes, 44093, France
  • Saint-Louis Hospital
    Paris, 75475, France
  • Miletrie Hospital, University Hospital Center of Poitiers
    Poitiers, 86021, France
  • University Hospital Freiburg, Department of Internal Medicine I
    Freiburg, Baden-Wuerttemberg D-79106, Germany
  • Klinikum Leverkusen gGmbH Medizinisxhe Klinik 3
    Leverkusen, North Rhine Westfalia 51375, Germany
  • Group Practice for Hematology and Oncology
    Dresden, Saxony 1307, Germany
  • Alexandra General Hospital, Therapeutic Clinic
    Athens, 11528, Greece
  • General Hospital of Athens "Evangelismos", Department of Hematology and Lymphoma
    Athens, Greece
  • University General Hospital of Patra
    Pátra, Greece
  • Theageneion Cancer Hospital, Hematology Department
    Thessaloníki, 54639, Greece
  • Semmelweis University, 1st Department of Internal Medicine
    Budapest, H-1083, Hungary
  • Integrated Szent Istvan and Szent laszlo Hospital, Department of Hematology and Stem Cell Transplantation
    Budapest, H-1097, Hungary
  • Semmelweis University, 3rd Department of Internal Medicine
    Budapest, H-1125, Hungary
  • Kaposi Mor Teaching Hospital, 2nd Department of Internal Medicine
    Kaposvar, 7400, Hungary
  • Medical Center of the University of Pecs, Department of Hematology
    Pecs, 7624, Hungary
  • Regional Cancer Centre
    Patna, Bihar 800014, India
  • Regional Cancer Centre
    Thiruvananthapuram, Kerala 695011, India
  • Prince Aly Khan Hospital
    Mumbai, Maharashta 400010, India
  • Jaslok Hospital and Research Centre
    Mumbai, Maharashta 400026, India
  • Bhaktivedanta Hospital
    Thane, Maharashtra 401107, India
  • IMS & SUM Hospital
    Bhubaneswar, Odisha 751003, India
  • Postgraduate Institute of Medical Education & Research (PGIMER)
    Chandigarh, Punjab 160012, India
  • Dayanand Medical College & Hospital
    Ludhiana, Punjab 141001, India
  • Cancer Institute
    Chennai, Tamil Nadu 600020, India
  • SRM Institute of Medical Sciences
    Chennai, Tamil Nadu 600026, India
  • Saveetha Medical College Hospital
    Chennai, Tamil Nadu 602105, India
  • G. Kuppuswamy Naidu Hospital
    Coimbatore, Tamil Nadu 641037, India
  • Asviratham Speciality Hospital
    Madurai, Tamil Nadu 625020, India
  • Meenakshi Mission Hospital
    Madurai, Tamil Nadu 625107, India
  • Yashoda Hospital
    Hyderabad, Telengana 500082, India
  • King George's Medical University
    Lucknow, Uttar Pradesh 226003, India
  • Netaji Subhash Chandra Bose Cancer Research Institute
    Kolkata, West Bengal 700094, India
  • Nil Ratan Sircar (NRS) Medical College
    Kolkata, West Bengal 700120, India
  • TATA Memorial Centre
    Kolkata, West Bengal 700160, India
  • Rajiv Gandhi Cancer Hospital
    New Delhi, 110085, India
  • Barzilai Medical Center
    Ashkelon, 7830604, Israel
  • Rambam Health Care Campus
    Haifa, 3109601, Israel

Showing the first 100 of 157 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Delimpasi S, Mateos MV, Auner HW, Gavriatopoulou M, Dimopoulos MA, Quach H, Pylypenko H, Hajek R, Leleu X, Dolai TK, Sinha DK, Venner CP, Benjamin R, Garg MK, Doronin V, Levy Y, Moreau P, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. Am J Hematol. 2022 Mar 1;97(3):E83-E86. doi: 10.1002/ajh.26434. Epub 2021 Dec 29. No abstract available. PubMed 34882831 ↗
  • Richard S, Chari A, Delimpasi S, Simonova M, Spicka I, Pour L, Kriachok I, Dimopoulos MA, Pylypenko H, Auner HW, Leleu X, Usenko G, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros A, Anderson LD Jr, Bahlis NJ, Facon T, Mateos MV, Cavo M, Chang H, Landesman Y, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Grosicki S, Richardson PG. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol. 2021 Sep 1;96(9):1120-1130. doi: 10.1002/ajh.26261. Epub 2021 Jul 5. PubMed 34062004 ↗
  • Mateos MV, Gavriatopoulou M, Facon T, Auner HW, Leleu X, Hajek R, Dimopoulos MA, Delimpasi S, Simonova M, Spicka I, Pour L, Kriachok I, Pylypenko H, Doronin V, Usenko G, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros AZ, Anderson LD Jr, Bahlis NJ, Cavo M, Chai Y, Jeha J, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. J Hematol Oncol. 2021 Apr 13;14(1):59. doi: 10.1186/s13045-021-01071-9. PubMed 33849608 ↗
  • Auner HW, Gavriatopoulou M, Delimpasi S, Simonova M, Spicka I, Pour L, Dimopoulos MA, Kriachok I, Pylypenko H, Leleu X, Doronin V, Usenko G, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros A, Anderson LD Jr, Bahlis NJ, Facon T, Mateos MV, Cavo M, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Richardson PG, Grosicki S. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Am J Hematol. 2021 Jun 1;96(6):708-718. doi: 10.1002/ajh.26172. Epub 2021 May 3. PubMed 33755235 ↗
  • Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020 Nov 14;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3. PubMed 33189178 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Feb 2020, 32 months.

Results were first posted in Jul 2021, 1 year 4 months after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 32 months is below that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2017
First posted
Apr 12, 2017
StartActual
May 24, 2017
Primary completionActual
Feb 18, 2020
CompletionActual
May 12, 2022
Results first posted
Jul 8, 2021
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03110562
Responsible party
Sponsor
First posted
Apr 12, 2017
Start date
May 24, 2017
Primary completion
Feb 18, 2020
Completion
May 12, 2022
Results posted
Jul 8, 2021
Last update
Aug 21, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Selinexor · Bortezomib

Start the discussion